Gilead Sciences (GILD) Total Liabilities (2009 - 2026)

Gilead Sciences has reported Total Liabilities for 18 years, with the latest figure at $32.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 12.3% year-over-year to $32.8 billion; the trailing twelve-month figure through Mar 2026 stood at $32.8 billion (down 12.3% YoY), and the FY2025 full-year result was $36.3 billion, down 8.63% from the prior year.
• Total Liabilities for Q1 2026 stood at $32.8 billion, down from $36.3 billion in the prior quarter.
• The five-year high for Total Liabilities was $43.2 billion in Q1 2022, with the low at $32.8 billion in Q1 2026.
• Historically, Total Liabilities has averaged $38.9 billion across 5 years, with a median of $39.4 billion in 2023.
• Annual changes were most pronounced in 2024 — Total Liabilities decreased 14.21% — and 2025, when it increased 2.37%.
• Gilead Sciences' Total Liabilities stood at $42.0 billion in 2022, then decreased by 6.16% to $39.4 billion in 2023, then advanced by 0.95% to $39.7 billion in 2024, then retreated by 8.63% to $36.3 billion in 2025, then retreated by 9.79% to $32.8 billion in 2026.
• The last three Total Liabilities figures came in at $32.8 billion (Q1 2026), $36.3 billion (Q4 2025), and $37.0 billion (Q3 2025), per Business Quant data.